Blood cholesterol levels predict risk of heart disease due to hormone therapyMay 27, 2008New analysis from the Women's Health Initiative A new analysis of a subgroup of participants in the Women's Health Initiative (WHI) hormone therapy clinical trials suggests that healthy, postmenopausal women whose blood cholesterol levels are normal or lower are not at increased, short-term risk for heart attack when taking hormone therapy. In particular, postmenopausal women who had no history of heart disease but whose ratio of low-density lipoprotein (LDL or "bad") cholesterol to high-density lipoprotein (HDL, or "good") cholesterol was less than 2.5 were at no increased risk of heart attack or death due to heart attack from taking estrogen plus progestin or estrogen alone, compared to their peers who did not take hormone therapy, after four years of follow up. "Usefulness of Baseline Lipids and C-Reactive Protein in Women Receiving Menopausal Hormone Therapy as Predictors of Treatment-Related Coronary Events," will be published in the June 1 issue of the American Journal of Cardiology. The study was funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Michael S. Lauer, M.D., director of the NHLBI Division of Prevention and Population Sciences, is available to comment on this latest analysis of the WHI hormone therapy clinical trials. He emphasizes that the primary results of the WHI hormone therapy clinical trials indicate that, overall, neither form of hormone therapy reduces the risk of heart disease in healthy, postmenopausal women, and estrogen plus progestin increases a women's risk of heart disease. In addition, both estrogen plus progestin and estrogen alone increase the risk of stroke and blood clots - serious cardiovascular conditions that the new analysis does not address. Combination hormone therapy also increases the risk of breast cancer. Identifying which women are more likely to be at increased risk for heart attack when taking hormone therapy can help women and their clinicians make better informed decisions about whether the benefits of hormone therapy outweigh the risks. In general, however, women should not take hormone therapy to prevent heart disease, and women who choose to use hormone therapy for menopausal symptoms should use the lowest possible dose for the shortest duration. In addition, all women whose blood cholesterol levels are elevated are at increased risk of heart disease, regardless of whether they use hormone therapy, and they should take steps to lower their risk. Heart disease is the leading cause of death among both women and men in the United States. NIH/National Heart, Lung and Blood Institute | |||||||||||||||||||||
|
Related Hormone Therapy News Articles Hormone replacement therapy improves sleep, sexuality and joint pain in older women One of the world's longest and largest trials of hormone replacement therapy (HRT) has found that post-menopausal women on HRT gain significant improvements in quality of life. Why a common treatment for prostate cancer ultimately fails Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences. Growth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapy Low-dose growth hormone treatment reduced abdominal fat deposits and improved blood pressure and triglyceride levels in a group of patients with HIV lipodystrophy, a condition involving the redistribution of fat and other metabolic changes in patients receiving combination drug therapy for HIV infection. Prostate cancer vaccines more effective with hormone therapy Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research. Treatment delays result in poor outcomes for men with breast cancer Men who develop breast cancer are often not treated until the disease has spread to the point that treatment becomes difficult, new results show. Elevated biomarkers predict risk for prostate cancer recurrence A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease. Complex Changes in the Brain's Vascular System Occur after Menopause Many women experience menopausal changes in their body including hot flashes, moodiness and fatigue, but the changes they don't notice can be more dangerous. Estrogen therapy helps or hurts the brain depending on reproductive status Estrogen therapy may limit stroke damage if started close to, but not long after reproductive cycles are over, according to a new animal study. The results were presented Sunday, June 15, at The Endocrine Society's 90th Annual Meeting in San Francisco. Long-term hormone replacement therapy increases breast cancer risk "Are you taking or did you take hormones? If yes, which hormone medication and for how long? When did you stop taking hormone replacement medication?" 3,464 breast cancer patients and 6,657 healthy women between the ages of 50 and 74 years participated in a large survey and elicited detailed information about hormone replacement medications they are taking or used to take for relief of menopausal symptoms. Study finds it pays to be heart smart if considering hormone therapy A research study has found that a simple blood test may indicate whether post-menopausal hormone therapies present an elevated risk of a heart attack. More Hormone Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||